Stockscreener 앱 받기
1.51
0.00%
0.00
전일 마감가:
$1.51
열려 있는:
$1.52
하루 거래량:
304.39K
Relative Volume:
2.00
시가총액:
$24.75M
수익:
-
순이익/손실:
$-8.29M
주가수익비율:
-2.1571
EPS:
-0.7
순현금흐름:
$-6.47M
1주 성능:
-1.95%
1개월 성능:
+20.80%
6개월 성능:
+2.03%
1년 성능:
-41.47%
1일 변동 폭
$1.45
$1.53
1주일 범위
$1.45
$1.57
52주 변동 폭
$0.94
$2.579
NanoViricides Inc Stock (NNVC) Company Profile
명칭
NanoViricides Inc
전화
203-937-6137
주소
1 Controls Drive, Shelton, CT
NNVC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.51 | 24.75M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2015-02-11 | 개시 | Midtown Partners | Strong Buy |
NanoViricides Inc 주식(NNVC)의 최신 뉴스
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise - citybuzz -
NanoViricides Measles Drug Development Animal Study is Imminent - Akron Beacon Journal
Small cap wrap: NanoViricides, New Era Helium, Charbone Hydrogen, Voyageur Pharmaceuticals... - Proactive financial news
NanoViricides commissions animal study of broad-spectrum antiviral for measles - Proactive Investors
NanoViricides (NNVC) Advances Measles Drug Development | NNVC St - GuruFocus
Breakthrough Measles Drug Enters Critical Testing Phase as Global Cases Surge 10X - Stock Titan
Nanoviricides (NNVC) To Unveil 'Escape-Proof' Antiviral Platform At Major Biotech Convention - MENAFN.com
NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotech Convention - openPR.com
Gold Is Bullish, But Be Aware Of Deeper Intraday Pullback; Elliott Wave Intraday Analysis - The Globe and Mail
NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention - The Globe and Mail
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 - Lohud
NanoViricides to Showcase Breakthrough Antiviral Platform at BIO International Convention - citybuzz -
Hudbay Receives TSX Approval for Normal Course Issuer Bid - The Globe and Mail
NanoViricides to present at BIO International Convention 2025 in Boston - Proactive financial news
NanoViricides president backs FDA's targeted COVID booster policy shift - Proactive financial news
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan - ACCESS Newswire
Small cap wrap: NanoViricides, Trust Stamp, NextSource, StickIt... - Proactive financial news
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox - Proactive Investors
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in AfricaPhase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu - thederrick.com
NanoViricides: MPox ethics approval enables Phase 2 application - Proactive Investors
NanoViricides: Fiscal Q3 Earnings Snapshot - Huron Daily Tribune
Small cap wrap: atai, Black Swan Graphene, TNR Gold, NanoViricides... - Proactive financial news
NanoViricides progresses antiviral portfolio as measles and MPox threats rise - Proactive financial news
Measles Cases Are Increasing Globally; MPox Continues to Be a ThreatBroad-Spectrum Antiviral Drug Could Be the Solution - The Derrick
AMAT Likely to Beat Q2 Earnings Estimates: How to Play the Stock - The Globe and Mail
Small cap wrap: NanoViricides, Alvopetro, Polarean... - Proactive financial news
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC - Proactive financial news
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo - The Derrick
Renaissance Technologies LLC Buys 30,800 Shares of NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides to Present Innovative Antiviral Drug Research at D. Boral Capital Conference - citybuzz -
NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC - The Globe and Mail
Geode Capital Management LLC Acquires 31,956 Shares of NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Advances Broad-Spectrum Antiviral Drug for Measles Treatment - citybuzz -
NanoViricides advances measles drug development amid rising US cases | NYSE-A:NNVC - Proactive financial news
Press Release Distribution & PR Platform - ACCESS Newswire
Measles is Likely to Become EndemicNanoViricides Is Testing a Drug to Combat It - The Derrick
NanoViricides advances measles drug development amid rising US cases - Proactive financial news
NanoViricides Inc (NNVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):